Gabrielsen Comments on Trump Administration’s Imposition of New Limits on ‘Guidance Documents’
10 February 2018
Associate Lindsey Gabrielsen is quoted in a New York Times article, “Administration Imposes Sweeping Limits on Federal Actions Against Companies,” about the ramifications of the Justice Department’s adoption of new limits on the use of ‘guidance documents” by federal agencies.
In view of the new policy, Gabrielsen said, the government “will face serious hurdles” in enforcement actions based on violations of health care guidance documents.
Gabrielsen’s comments to the New York Times were also republished in Esquire, FierceHealthcare and MSN.
In view of the new policy, Gabrielsen said, the government “will face serious hurdles” in enforcement actions based on violations of health care guidance documents.
Gabrielsen’s comments to the New York Times were also republished in Esquire, FierceHealthcare and MSN.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”